Ribozyme therapeutics: These versatile molecules are emerging as a potential new class of drugs

Nature Biotechnology

Volumn 15, Issue 9, 1997, Pages 921-922

  Persidis, Aris ^a  

^a Upstate Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN SYNTHESIS INHIBITOR; RIBOZYME;

CARDIOVASCULAR DISEASE; CHEMISTRY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG DESIGN; ECONOMICS; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC BONE DISEASE; METABOLISM; NEOPLASM; REVIEW; VIRUS HEPATITIS; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; GENE TECHNOLOGY; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

BONE DISEASES, METABOLIC; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG DESIGN; GENE THERAPY; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; NEOPLASMS; PROTEIN SYNTHESIS INHIBITORS; RNA, CATALYTIC; RNA, MESSENGER;

EID: 0031225829     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0997-921     Document Type: Article

References (16)

1. Draper, D.E. 1996. Strategies for RNA folding. Trends in Biochem. Sci. 21:145-149.
2. Wilson, C. and Szostak, J.W. 1995. In vitro evolution of a self-alkylating ribozyme. Nature 374:777-782.
3. Visser, C.M. 1984. Evolution of biocatalysis. J. Mol. Evol. 14:301-306.
4. Cech, T., et al. 1981. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: Involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 27:487-496.
5. Jaeger, L 1997. The new world of ribozymes. Curr. Opin. Struct Biol. 7:324-335.
6. Ishizaka, M., Ohshlma Y., and Tani, T. 1995. Isolation of active ribozymes from an RNA pool of random sequences using an anchored substrate RNA. Biochem Biophys. Res. Comm. 214:403-409.
7. Persidis, A. 1997. Industry Trends: Combinatorial chemistry. Nature Biotechnology 15:391-392.
8. Ekland, E.H. and Bartel, DP. 1995. The secondary structure and sequence optimization of an RNA ligase ribozyme, Nucl. Acids Res. 23:3231-3238.
9. Mamounas, M. and Yu, M. 1996. Gene therapy for the treatment of viral infections. Infection in Med. 13:817-823.
10. Rossi, J.J. 1996. Controlled, targeted, intracellular expression of ribozymes: Progress and problems. Trends Biotechnol. 13:301-306.
11. Gibson, S.A. and Shillitoe, E.J. 1997. Ribozymes: Their functions and strategies for their use. Mol. Biotechnol. 7:125-137.
12. Sigurdsson, S.T. and Eckstein, F. 1995. Structure-function relationships of hammerhead ribozymes: From understanding to applications. Trends Biotechnol. 13:286-289.
13. Sun, L.Q., Ely, J.A., Gerlach, W., and Symonds, G. 1997. Anti-HIV ribozymes. Mol. Biotechnol. 7:241-251.
14. Pyle, A.M. 1993. Ribozymes: A distinct class of metalloenzymes. Science 261:709-714.
15. Scott, W.G., et al. 1995. The crystal structure of an all-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage. Cell 81:991-1002.
16. Sigurdsson, S.T. and Eckstein, F. 1995. Structure-function relationships of hammerhead ribozymes: From understanding to applications. Trends Biotechnol. 13:286-289.